PHARMAENGINE, INC. (TWO.4162)
4Q 2025 INVESTORS' CONFERENCE
2026/03/09

ChiHsing Chang, Vice President/Spokesperson

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. **Pricing and product initiatives of competitors**
2. **Legislative and regulatory developments and economic conditions**
3. **Delay or inability in obtaining regulatory approvals or bringing products to market**
4. **Fluctuations in currency exchange rates and general financial market conditions**
5. **Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products**
6. **Increased government pricing pressures**
7. **Interruptions in production**
8. **Loss of or inability to obtain adequate protection for intellectual property rights**
9. **Litigation**
10. **Loss of key executives or other employees**
11. **Adverse publicity and news coverage**

PharmaEngine cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. PharmaEngine undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that PharmaEngine ’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of PharmaEngine, Inc.

AGENDA

1. 2025 Operational Highlights
2. 2025 Operational Overview
3. R&D Pipeline Strategy & Outlook
4. Q&A

PharmaEngine
智 擎 生 技 製 藥

2025 Operational Highlights: Sustainable Growth and Enhanced Pipeline

COMMERCIAL

ONIVYDE® Indication expansion

1. 2024 Europe and Asia sales reached milestone target, PharmaEngine received US$50 million for ONIVYDE's second sales milestone.
2. 1L combination therapy of ONIVYDE® obtained approvals in various EU countries, boosting revenue growth
3. Included in Taiwan's health insurance reimbursement for first-line treatment of PDAC starting in December 2025.

PIPELINE

New project R&D progress accelerated

1. PEP07 Phase I clinical trials for hematologic/solid tumor cancers gradually completed MTD finding and will continue with dose expansion.
2. PEP08 Phase I clinical trial for solid tumors was approved by Australia's HREC and Taiwan's TFDA, the first patient was dosed in October 2025.
3. Other projects continue to move forward.

OPERATION

Operation with sustainable growth

1. Cash dividend payout for the 12th consecutive year; 2025 cash dividend: NT$2/share
2. Completed the CDMO part of the second phase of scope 3 GHG inventory, data to be presented in 2025 Sustainability Report.

PharmaEngine
智 擎 生 技 製 藥

2025 OPERATIONAL OVERVIEW

Sales and Royalties Drive Long-Term Growth

NT$(000)

Item / Year	2019	2020	2021	2022	2023	2024	2025 YOY (%)
Taiwan Sales	180,389	214,828	235,469	277,594	278,547	279,990	277,133 (-1%)
Royalties from Europe and Asia	133,651	271,584	419,366	376,789	426,652	543,286	627,762 (+15.5%)
Milestone/Sub-license Revenue	0	569,600	0	0	62,470	1,700,028	6,521 (-99.6%)
Total	314,040	1,056,012	654,835	654,383	767,669	2,523,304	911,416 (-63.9%)

2025 Financial Results

NT$(000)	2025	2024	Amount Change	% Change
Operating revenue	911,416	2,523,304	(1,611,888)	-64%
Operating costs	51,853	47,740	4,113	9%
Gross profit	859,563	2,475,564	(1,616,001)	-65%
Sales expenses	36,866	37,605	(739)	-2%
G&A expenses	97,520	117,768	(20,248)	-17%
R&D expenses	299,716	267,025	32,691	12%
Total operating expenses	434,102	422,398	11,704	3%
Operating income	425,461	2,053,166	(1,627,705)	-79%
Total non-operating income and expenses	83,832	109,829	(25,997)	-24%
Income before income tax	509,293	2,162,995	(1,653,702)	-76%
Income tax expense	121,652	411,965	(290,313)	-70%
Profit for the period	387,641	1,751,030	(1,363,389)	-78%
EPS (NT$)	2.70	12.19	(9.49)	-78%

PharmaEngine
智 擎 生 技 製 藥

R&D PIPELINE STRATEGY & OUTLOOK

Pipeline Portfolio Focuses on Precision Oncology

Program		Indications	Lead	Preclinical	Phase I	Phase II	Phase III	Approval	Commercial Rights	Partner
ONIVYDE® (liposomal irinotecan)		1L/2L PDAC	Approval						Milestone Royalty (EU/Asia) Taiwan Sales	IPSEN Innovation for patient care
DDR & Synthetic Lethality	PEP07 (CHK1i)	AML/MCL				Dose expansion phase			Global	Sentinel ONCOLOGY
		Solid tumors				Dose expansion phase				
	PEP08 (PRMT5i)	MTAP-del cancers							Global	PEI Owned
	PEP09	Undisclosed							Global	Undisclosed
	PEP10	Undisclosed							Global	PEI Owned

PEP07: CHK1 is Key to Cell Survival



CHK1 is a key in cell cycle regulation and DNA damage repair. When cell DNA is damaged, CHK1 will be activated to repair DNA damage and avoid incorrect inheritance. If the damage cannot be repaired, CHK1 will promote cell apoptosis.



PEP07 inhibits CHK1 function, therefore, if cell repair and replication experience any issues, it will not be able to recover and will lead to cell apoptosis.

PEP07 Phase I Clinical Trial Plan

Phase I Mono — dose escalation in **hematologic cancers (first patient dosed in 2023/08)** → **Phase I Mono** — dose expansion in **AML and MCL** → **Phase I Combo** — Target: **AML and MCL**

Phase I Mono — dose escalation in advanced or metastatic **solid tumors (first patient dosed in 2024/04)** → **Phase I Mono** — dose expansion in **selected indications** → **Phase I Combo** — Target: **selected indications**

Preclinical biomarker study is ongoing for further design of clinical trials.

Rationale of Monotherapy Inadequacy

1. Pre-existing genetic resistance mutations

2. Acquired resistance mutations



3. Non-genetic adaptation to targeted therapy

PEP07: Potential Indications, Number of Patients, and Market Size Forecast

Number of Potential Patients of Selected Indications (2022)



Global DDR Drugs Market Size Forecast



Source: Globocan 2022, HKEX Publication, 2026

PEP08 Mechanism of Action: Synthetic Lethality

- ✓ Second-generation MTA-co-operated PRMT5 inhibitors target only MTAP-deficient cancer cells, causing cancer cell death through the synthetic lethality mechanism..



MTAP-deleted cancer cells rely on PRMT5 function

MTAP homozygous deletion and PRMT5 inhibition cause synthetic lethality for cancer cells

PEP08: Potential Indications, Number of Patients, and Market Size Forecast

Eligible MTAP-Deletion Patients of Selected Indications (2022)



Global Synthetic Lethality Drugs Market Size Forecast



Source: Globocan 2022, HKEX Publication, 2026

Deal Values of DDR/Synthetic Lethality Drugs in 2020-2025

Target	Name	Licensor	Licensee	Date	Phase at Deal	Upfront	Total Deal Value	Territory
Eight DDR Targets	**N/A**	Artios	Merck	Dec. 2020	IND Candidates	US$30M	US$890M	Worldwide
Three DDR Targets	**N/A**	Artios	Novartis	Apr. 2021	Discovery	US$20M	US$1.3B	Worldwide
WEE1	**SPH6162**	Shanghai Pharmaceuticals	HUYABIO	Nov. 2021	Preclinical	Undisclosed	Undisclosed	Worldwide (exclude Greater China)
ATR	**RP-3500**	Repare Therapeutics	Roche	Jun. 2022	Preclinical	US$135M	US$1.2B	Worldwide
KIF18A	**Sovilnesib (AMG650)**	Amgen	Volastra Therapeutics	Mar. 2023	Phase I	Undisclosed	Undisclosed	Worldwide
PARP1	**HRS-1167**	Hengrui	Merck	Oct. 2023	Preclinical	€160M	€1.4B	Worldwide (exclude China)
CHK1	**SRA-737**	CRT Pioneer Fund	Private US biopharma	Jan. 2024	Phase II	US$0.5M	US$290M and 500,000 shares	Worldwide
KIF18A	**MEN2501**	InSilicon	Stemline Therapeutics	Jan. 2025	Preclinical	US$20M	US$550M	Worldwide
WRN	**VVD-214**	Roche	Vividion	Jun. 2025	Phase I	Undisclosed	Undisclosed	Worldwide
PKMYT1	**Lunresertib**	Repare Therapeutics	Debiopharm	Jul. 2025	Phase I	US$10M	US$267M	Worldwide

Deal Values of PRMT5/MAT2A Drugs in 2020-2026

Target	Name	Licensor	Licensee	Date	Phase at Deal	Upfront	Total Deal Value	Territory
MAT2A, Pol Theta and Werner Helicase	**IDE397**	Ideaya	GSK	Jun. 2020	Preclinical	US$100M US$20M stock US$50M exercise fee for MAT2A		50% US profit share and ex-US royalties
PRMT5	**MRTX1719**	Mirati	BMS	Oct. 2023	Phase 1	1. US$4.8B equity acquired 2. ~US$1B upon acceptance by FDA of NDA for MRTX1719 in NSCLC		
MAT2A	**SYH2039**	CSPC	BeiGene	Dec. 2024	Phase 1	US$150M	US$1.835B	Worldwide
PRMT5	**PH020**	Puhe BioPharma	Bayer	Mar. 2025	Phase I	Undisclosed	Undisclosed	Worldwide
MAT2A	**GH31**	Genhouse Bio	Gilead	Feb. 2026	IND	US$80M	US$1.450B	Worldwide

Partnering Strategy

2026-2030

- **Global Licensing: Worldwide rights exclude Taiwan**
- **Regional Licensing: China and Japan**
- **Collaboration: Treatment combo, e.g. SoC, new regimen**

Company Outlook for 2026-2030

New Dosage Form → Transformation → **New Chemical Entity** → Pipeline Build-up → **Precision Oncology (DDR & SL)**

2021

ONIVYDE® (Commercial)

2022 – 2025

PEP07 (Preclinical → Phase I)

AI-driven Drug Discovery Projects:
PEP08 (Drug Discovery → Preclinical → Phase I)
PEP09 (Drug Discovery → Late Drug Discovery/Lead Optimization)
PEP10 (Drug Discovery → Late Drug Discovery/Lead Optimization)

2026 – 2030

PEP07 (Expansion → Phase II/III)

AI-driven Drug Discovery Projects:
PEP08 (Expansion → Phase II/III)
PEP09 (Preclinical → IND-enabled study → Phase I)
PEP10 (Preclinical → IND-enabled study → Phase I)

PEPXX *(Candidate Nomination)*

Expand DDR and synthetic lethality pipeline dimension & target global precision oncology burgeoning market

THANK YOU

PharmaEngine
智 擎 生 技 製 藥